Professor Sunil Lakhani is the Chair of the BCT Board of Directors. He was elected to the Board in July 2017 and was appointed Chair of the Board in September 2021.
He is the Executive Director of Research and Senior Staff Specialist at Pathology Queensland and Head of the Breast Group, Centre for Clinical Research, University of Queensland, Brisbane, Australia.
He is a clinical diagnostic pathologist and also heads a research team comprising scientists and clinicians, ensuring a translational focus to the program. His current research interests include lobular carcinoma and its variants, establishing whole genome sequencing for high risk primary familial and sporadic breast cancers and mechanisms and therapeutic developments of brain and distant metastases. He is study pathologist and member of steering and translational committees for the OlympiA trial (PARPi Olaparib in BRCA1/2 early breast cancers).
He was Series Editor of the 4th Edition WHO Tumour Classification Monographs and Volume Editor of the WHO 4th Ed Tumours of the Breast (2012) and standing member of the Board for the WHO 5th Edition (2017-2021). He is the recipient of the Distinguished Pathologist Medal, International Academy of Pathology (2015); the BCT’s Robert Sutherland Award for Excellence in Translational Research (2016); The Distinguished Fellow Award, The Royal College of Pathologists of Australasia (2017), William O Russell and Joanne Vandenberg Award, MD Anderson Cancer Centre (2017) and The William L. Gerald Award, Memorial Sloane Kettering Cancer Center, New York USA (2021). In 2017, he was elected Fellow of the Australian Academy of Health and Medical Sciences.